评估134Ce/134La-PSMA-617用于前列腺癌PET显像与俄歇电子治疗的研究
本研究以PSMA-617为载体,评估134Ce/134La放射性核素对用于前列腺癌PET显像与俄歇电子治疗的潜力。体外实验显示对PSMA阳性PC3 PIP细胞有高结合率与内化率,克隆形成实验显示剂量依赖性细胞增殖下降(P=0.002);体内PET显像显示早期肿瘤高摄取,治疗实验中小鼠中位生存期较生理盐水对照组显著延长。
要点
- PSMA-617经134Ce/134La标记后摩尔活度达21.02±0.11 MBq/nmol,小鼠血清中5天稳定性超过95%。
- PSMA阳性PC3 PIP细胞结合率89.6%±0.55%,24小时内化率55.45%±0.96%,解离常数32.9±3.9 nM。
- 体内治疗小鼠中位生存期:生理盐水组33天,37 MBq组50天,111 MBq组80天(研究终点)。
核心结论
- [134Ce]Ce-PSMA-617在体外和体内均表现出良好特性,在小鼠中提供显著生存获益;这些发现提示其是用于前列腺癌PET显像与俄歇电子治疗的有效诊疗一体化药物。
研究设计与样本
- 研究对[134Ce]Ce-PSMA-617进行放射性标记并优化C18柱纯化,在PSMA阳性PC3 PIP细胞中进行体外结合与毒性实验。
- 在荷PSMA阳性PC3 PIP与PSMA阴性PC3 flu双瘤裸鼠中进行注射后1至72小时多个时间点的体内PET显像与离体生物分布研究。
- 在荷PC3 PIP肿瘤异种移植裸鼠中进行体内单次剂量治疗研究,剂量为37 MBq与111 MBq。
主要发现
- PSMA-617成功经134Ce/134La标记并以C18柱法纯化,摩尔活度为21.02±0.11 MBq/nmol;小鼠血清中5天稳定性超过95%。
- PSMA阳性PC3 PIP细胞结合率为89.6%±0.55%,24小时内化率为55.45%±0.96%,解离常数为32.9±3.9 nM,与其他报道的[177Lu]Lu/[225Ac]Ac-PSMA-617放射复合物相当。
- PSMA阴性PC3 flu细胞未观察到细胞摄取或内化。
- [134Ce]Ce-PSMA-617克隆形成实验显示细胞增殖呈显著剂量依赖性下降(P=0.002)。
- PET显像显示早期时间点(1和4小时)肿瘤高特异性摄取,随后24至72小时逐渐下降,正常组织快速清除;离体生物分布研究结果与之相符。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 134Ce/134La radionuclide pair has been proposed as a PET imaging surrogate for targeted α-radiotherapeutics. 134Ce decays to 134La via electron capture, emitting Auger electrons (AEs), which could be used for targeted radionuclide therapy. Additionally, the positron emission during this transition enables PET imaging, making 134Ce/134La a promising theranostic pair for prostate cancer. In this work, we investigated the potential of 134Ce for AE capture therapy using prostate-specific membrane antigen (PSMA)-617 for targeted radionuclide delivery. Methods: Radiolabeling of [134Ce]Ce-PSMA-617 proceeded as previously described, and C18 cartridge purification was optimized. In vitro, cell-binding and toxicity assays were performed on PSMA-positive PC3 PIP cells. In vivo PET imaging and ex vivo biodistribution studies were conducted on mice bearing dual PSMA-positive PC3 PIP and PSMA-negative PC3 flu tumor xenografts at various time points ranging from 1 to 72 h after injection. Additionally, an in vivo single-dose-treatment study was performed using 37- and 111-MBq doses in nude mice with PC3 PIP tumor xenografts. Results: PSMA-617 was successfully radiolabeled with 134Ce/134La and purified using the C18 cartridge method, achieving high molar activity (21.02 ± 0.11 MBq/nmol). Stability studies showed more than 95% stability in mouse serum at day 5. PSMA-positive PC3 PIP cells demonstrated 89.6% ± 0.55% cell binding, 55.45% ± 0.96% internalization at 24 h, and a dissociation constant of 32.9 ± 3.9 nM, comparable to other reported [177Lu]Lu/[225Ac]Ac-PSMA-617 radiocomplexes. In contrast, no cellular uptake or internalization was observed in PSMA-negative PC3 flu cells. Clonogenic assay of [134Ce]Ce-PSMA-617 showed a significant dose-dependent reduction in cell proliferation (P = 0.002). PET imaging revealed high tumor-specific uptake at early time points (1 and 4 h), followed by a gradual decline from 24 to 72 h, with rapid clearance from normal tissues. These results were corroborated by ex vivo biodistribution studies. In vivo therapy with [134Ce]Ce-PSMA-617 in tumor-bearing mice demonstrated a significant increase in median survival compared with control animals (saline, 33 d; 37 MBq, 50 d; and 111 MBq, 80 d, end of the study). Conclusion: [134Ce]Ce-PSMA-617 exhibited excellent in vitro and in vivo characteristics, providing significant survival benefits in mice. Collectively, these findings suggest that [134Ce]Ce-PSMA-617 is an effective theranostic agent for PET imaging and AE therapy of prostate cancer.
引用
- Bobba KN, Wadhwa A, Bidkar AP, et al. Evaluation of 134Ce/134La-PSMA-617 for PET Imaging and Auger Electron Therapy of Prostate Cancer. J Nucl Med. 2025. PMID: 40506238. doi:10.2967/jnumed.125.269751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。